Proceeds from the Placement will directly support the execution of the company’s pivotal US FDA 510(k) regulatory trial for clearance as an aid in the diagnostic process for autism; a key inflection point that underpins BlinkLab’s pathway to becoming a clinically validated, scalable diagnostic platform in one of the largest and most underserved areas in paediatric healthcare.
In parallel, funds will accelerate the company’s European regulatory strategy, including CE marking and compliance with EU Medical Device Regulation (MDR) requirements, positioning the BlinkLab Dx1 platform for access across major international markets.
In addition, a portion of the proceeds will be allocated to advancing the company’s US-focused ADHD programme, including the initiation of clinical studies to expand BlinkLab’s platform into this significantly larger and complementary market opportunity.
This funding will accelerate the transition of BlinkLab’s Dx1 technology platform from clinical validation into late-stage regulatory and commercial readiness. With strong pilot data already exceeding FDA- agreed performance thresholds for BlinkLab Dx1,1 the dompany is now focused on delivering robust, real-world evidence through its registrational program, while simultaneously building the operational, regulatory and market access foundations required for commercial launch in the United States (US).
